Repligen (RGEN) is trading higher as the market looks ahead to the company’s next earnings catalyst: first-quarter 2026 results due Tuesday, May 5, 2026, before the market opens, followed by a morning conference call. With no fresh company announcement tied specifically to April 30, the move appears driven by positioning into earnings after a volatile period for bioprocessing suppliers and heightened sensitivity to near-term demand signals.

The near-term trade is framed by expectations for Q1 performance and by the company’s full-year targets. For FY2026, Repligen has guided to $810 million–$840 million in revenue and $1.93–$2.01 in adjusted (non-GAAP) diluted EPS, which investors will watch for reaffirmation or adjustment on the May 5 update. Street-level estimates for Q1 vary by data source, but the focus remains on whether Repligen can deliver steady sequential momentum and defend its organic growth and margin expansion narrative into mid-2026.

Traders are likely to key on order trends, customer inventory digestion, and any commentary that clarifies whether February–March softness fears are easing. Segment commentary—particularly around analytics/process analytics and core bioprocessing consumables—could matter as much as the headline beat/miss. Any change in tone on demand visibility, gross margin trajectory, or capital allocation priorities could also swing the stock given the elevated attention into the print.